

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7129601

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CORIOLIS PHARMA RESEARCH GMBH	04/26/2021
RECEIVING PARTY DATA	
Name:	NEOTOPE NEUROSCIENCE LIMITED
Street Address:	77 SIR JOHN ROGERSON'S QUAY
Internal Address:	BLOCK C, GRAND CANAL DOCKLANDS
City:	DUBLIN 2
State/Country:	IRELAND
Postal Code:	D02 VK60
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16767994
CORRESPONDENCE DATA	
Fax Number:	(704)444-1111
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6508382000
Email:	Angela.Pham@alston.com
Correspondent Name:	ALSTON & BIRD LLP
Address Line 1:	BANK OF AMERICA PLAZA
Address Line 2:	101 SOUTH TRYON STREET, SUITE 4000
Address Line 4:	CHARLOTTE, NORTH CAROLINA 28280
ATTORNEY DOCKET NUMBER:	071832-541985
NAME OF SUBMITTER:	SUSAN K. SATHER
SIGNATURE:	/Susan K. Sather/
DATE SIGNED:	01/19/2022
Total Attachments: 3	
source=541985US Executed Assignment (Coriolis to Neotope)#page1.tif	
source=541985US Executed Assignment (Coriolis to Neotope)#page2.tif	
source=541985US Executed Assignment (Coriolis to Neotope)#page3.tif	

ASSIGNMENT

THIS ASSIGNMENT, by CORIOLIS PHARMA RESEARCH GMBH, a corporation duly organized under and pursuant to the laws of Germany, and having its principal place of business at Fraunhoferstrasse 18b, 82152 Martinsried, Germany (hereinafter referred to as "Assignor"), witnesseth:

WHEREAS, Assignor is the owner of the entire right, title and interest in and to the invention set forth as follows:

Title of Invention: Lyophilized Formulation of a Monoclonal Antibody
Against Transthyretin

US Application No.: 16/767,994

Filing Date: November 28, 2018

WHEREAS, NEOTOPE NEUROSCIENCE LIMITED, a private limited company incorporated under the laws of Ireland, and having its registered office at 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 T804, Ireland (hereinafter referred to as "Assignee"), pursuant to the Research and Development Agreement effective August 14, 2015, by and between Assignor and Prothena Biosciences Limited ("PBL"), as amended by Amendment Number One to the Service and Development Agreement, dated July 29, 2016, and as assigned to Assignee by PBL, effective October 1, 2020 (hereinafter referred to as "the R&D Agreement") between Assignor and Assignee, has acquired Assignor's right, title, and interest in and to the above-mentioned application and invention, the right to file applications on said invention, and the right, title and interest in and to any applications, including provisional applications, on said invention for Letters Patent of the United States or other countries, and any applications claiming priority to said applications, and in and to any Letters Patent or Patents of any country, to be obtained therefor and thereon;

NOW, THEREFORE, pursuant to the R&D Agreement, for good and sufficient consideration, the receipt of which is hereby acknowledged, Assignor has assigned, transferred, and set over, and by these presents does assign, transfer, and set over unto Assignee, and Assignee's successors, legal representatives, and assigns, all of Assignor's right, title, and interest in and to the above-mentioned invention and application, the right to file applications on said invention and the right, title and interest in and to any such applications, including provisional applications, and any applications claiming priority from said applications for Letters Patent of the United States or other countries, and any and all Letters Patent or Patents of the United States of America and all foreign countries that have been or may be granted therefor and thereon, and in and to any and all divisions, renewals, substitutions, conversions, continuations, and continuations-in-part of said applications, and reissues, prolongations and extensions of said Letters Patent or Patents, and all rights under the Paris Convention for the Protection of Industrial Property, including the right to claim priority, the same to be held and enjoyed by Assignee, for its own use

and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by Assignor had its assignment not been made;

AND Assignor hereby covenants that Assignor has the full right to convey the interest assigned by this Assignment, and Assignor has not executed and will not execute any agreement in conflict with this Assignment;

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives, and assigns, that Assignor shall, whenever counsel of Assignee, or the counsel of its successors, legal representatives, and assigns, advises that any proceeding in connection with said invention or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said invention in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said applications, division, continuation, continuation-in-part, substitution or conversion of any applications for Letters Patent or Patents, or any reissue, prolongation or extension of any Letters Patent or Patents to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention, without charge to Assignee, but at the cost and expense of Assignee, its successors, legal representatives, and assigns;

AND Assignor hereby requests the Commissioner of Patents to issue any and all said Letters Patent or Patents of the United States to Assignee as the assignee of said invention and the Letters Patent or Patents issued and to be issued thereon for the sole use and behalf of Assignee, its successors, legal representatives, and assigns.

IN TESTIMONY WHEREOF, a duly authorized representative of Assignor has signed on the date indicated.

CORIOLIS PHARMA RESEARCH GMBH

Date: 26. April 2021

By: DocuSigned by:
Michael Wiggendorff
00311F8F5C10332

Printed Name: Dr. Michael Wiggendorff
Title: Managing Director

IN TESTIMONY WHEREOF, a duly authorized representative of Assignee has signed on the date indicated.

NEOTOPE NEUROSCIENCE LIMITED

Date: 28 April 2021

By: Olivia Waldron

Printed Name: Olivia Waldron

Title: Assistant Company Secretary